TTA-A2 Catalog No.:M26158-C 25 µg/mL) suppresses TNFα

25 µg/mL) suppresses TNFα

selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3

and that both lobes are required for binding to receptor8

Ivermectin is a mixture of mostly avermectin H2B1a (CAS# 71827-03-7) with some avermectin H2B1b (CAS# 70209-81-3)

39)40)22-33(37)43-2/h5-20H

TTA-A2 Catalog No.:M26158-C 25 µg/mL) suppresses TNFαTTA A2 is a potent, selective and orally active t type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA A2 is equally potent against the Cav3. 1 (a1G) and Cav3. 2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at 80 and 100 mV holding potentials. TTA A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy. Product information